705 related articles for article (PubMed ID: 25818266)
1. Management of resistant hypertension: aldosterone antagonists or intensification of diuretic therapy?
Verdalles U; García de Vinuesa S; Goicoechea M; Macías N; Santos A; Perez de Jose A; Verde E; Yuste C; Luño J
Nephrology (Carlton); 2015 Aug; 20(8):567-71. PubMed ID: 25818266
[TBL] [Abstract][Full Text] [Related]
2. Chronic kidney disease progression in patients with resistant hypertension subject to 2 therapeutic strategies: Intensification with loop diuretics vs aldosterone antagonists.
Verdalles U; Goicoechea M; García de Vinuesa S; Torres E; Hernández A; Verde E; Pérez de José A; Luño J
Nefrologia (Engl Ed); 2020; 40(1):65-73. PubMed ID: 31451203
[TBL] [Abstract][Full Text] [Related]
3. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade.
Khosla N; Kalaitzidis R; Bakris GL
Am J Nephrol; 2009; 30(5):418-24. PubMed ID: 19738369
[TBL] [Abstract][Full Text] [Related]
4. Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism.
Karagiannis A; Tziomalos K; Papageorgiou A; Kakafika AI; Pagourelias ED; Anagnostis P; Athyros VG; Mikhailidis DP
Expert Opin Pharmacother; 2008 Mar; 9(4):509-15. PubMed ID: 18312153
[TBL] [Abstract][Full Text] [Related]
5. Serum potassium levels predict blood pressure response to aldosterone antagonists in resistant hypertension.
Shlomai G; Sella T; Sharabi Y; Leibowitz A; Grossman E
Hypertens Res; 2014 Dec; 37(12):1037-41. PubMed ID: 24671013
[TBL] [Abstract][Full Text] [Related]
6. Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study - a randomized controlled trial.
Oliveras A; Armario P; Clarà A; Sans-Atxer L; Vázquez S; Pascual J; De la Sierra A
J Hypertens; 2016 Sep; 34(9):1863-71. PubMed ID: 27327441
[TBL] [Abstract][Full Text] [Related]
7. Sequential nephron blockade versus sequential renin-angiotensin system blockade in resistant hypertension: a prospective, randomized, open blinded endpoint study.
Bobrie G; Frank M; Azizi M; Peyrard S; Boutouyrie P; Chatellier G; Laurent S; Menard J; Plouin PF
J Hypertens; 2012 Aug; 30(8):1656-64. PubMed ID: 22728905
[TBL] [Abstract][Full Text] [Related]
8. Long-term effects of aldosterone blockade in resistant hypertension associated with chronic kidney disease.
Pisoni R; Acelajado MC; Cartmill FR; Dudenbostel T; Dell'Italia LJ; Cofield SS; Oparil S; Calhoun DA
J Hum Hypertens; 2012 Aug; 26(8):502-6. PubMed ID: 21677673
[TBL] [Abstract][Full Text] [Related]
9. The effect of spironolactone in patients with resistant arterial hypertension in relation to baseline blood pressure and secondary causes of hypertension.
Vaclavik J; Sedlak R; Jarkovsky J; Kocianova E; Taborsky M
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2013 Mar; 157(1):50-5. PubMed ID: 23128822
[TBL] [Abstract][Full Text] [Related]
10. Amlodipine and loop diuretics as the second anti-hypertensive medication for the treatment of hypertension with chronic kidney diseases.
Takenaka T; Uchida K; Kojima E; Gen S; Nodaira Y; Hoshi H; Kato N; Takane H; Ohno Y; Suzuki H
Clin Exp Hypertens; 2011; 33(4):210-5. PubMed ID: 21699446
[TBL] [Abstract][Full Text] [Related]
11. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes.
Epstein M; Williams GH; Weinberger M; Lewin A; Krause S; Mukherjee R; Patni R; Beckerman B
Clin J Am Soc Nephrol; 2006 Sep; 1(5):940-51. PubMed ID: 17699311
[TBL] [Abstract][Full Text] [Related]
12. Raised aldosterone to renin ratio predicts antihypertensive efficacy of spironolactone: a prospective cohort follow-up study.
Lim PO; Jung RT; MacDonald TM
Br J Clin Pharmacol; 1999 Nov; 48(5):756-60. PubMed ID: 10594479
[TBL] [Abstract][Full Text] [Related]
13. Spironolactone and Resistant Hypertension in Heart Failure With Preserved Ejection Fraction.
Rossignol P; Claggett BL; Liu J; Vardeny O; Pitt B; Zannad F; Solomon S
Am J Hypertens; 2018 Mar; 31(4):407-414. PubMed ID: 29228101
[TBL] [Abstract][Full Text] [Related]
14. Greater efficacy of aldosterone blockade and diuretic reinforcement vs. dual renin-angiotensin blockade for left ventricular mass regression in patients with resistant hypertension.
Azizi M; Perdrix L; Bobrie G; Frank M; Chatellier G; Ménard J; Plouin PF
J Hypertens; 2014 Oct; 32(10):2038-44; discussion 2044. PubMed ID: 24983187
[TBL] [Abstract][Full Text] [Related]
15. Utility of bioimpedance spectroscopy (BIS) in the management of refractory hypertension in patients with chronic kidney disease (CKD).
Verdalles U; de Vinuesa SG; Goicoechea M; Quiroga B; Reque J; Panizo N; Arroyo D; Luño J
Nephrol Dial Transplant; 2012 Dec; 27 Suppl 4():iv31-5. PubMed ID: 23258808
[TBL] [Abstract][Full Text] [Related]
16. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial.
Václavík J; Sedlák R; Plachy M; Navrátil K; Plásek J; Jarkovsky J; Václavík T; Husár R; Kociánová E; Táborsky M
Hypertension; 2011 Jun; 57(6):1069-75. PubMed ID: 21536989
[TBL] [Abstract][Full Text] [Related]
17. Spironolactone Add-on for Preventing or Slowing the Progression of Diabetic Nephropathy: A Meta-analysis.
Hou J; Xiong W; Cao L; Wen X; Li A
Clin Ther; 2015 Sep; 37(9):2086-2103.e10. PubMed ID: 26254276
[TBL] [Abstract][Full Text] [Related]
18. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT)--study protocol.
Vaclavik J; Sedlak R; Plachy M; Navratil K; Plasek J; Husar R; Kocianova E; Taborsky M
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2011 Jun; 155(2):143-8. PubMed ID: 21804623
[TBL] [Abstract][Full Text] [Related]
19. Eplerenone, an aldosterone blocker, is more effective in reducing blood pressure in patients with, than without, metabolic syndrome.
Suzuki H; Shuto H; Shuto C; Ohara I; Inokuma S; Abe Y; Sukigara M
Ther Adv Cardiovasc Dis; 2012 Aug; 6(4):141-7. PubMed ID: 22751654
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of low dose spironolactone in chronic kidney disease with resistant hypertension.
Abolghasmi R; Taziki O
Saudi J Kidney Dis Transpl; 2011 Jan; 22(1):75-8. PubMed ID: 21196617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
